Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

H. Lundbeck A/S

http://www.lundbeck.com

Latest From H. Lundbeck A/S

Trials In Focus: Diverse Enrollment Lagging In Oncology, IQVIA Finds

Also, CRO Syneos Health appointed an executive to its newly created DE&I position, while Alterity started a new Phase II study in multiple system atrophy, Antabio dosed the first patients in its Phase I study of an antibiotic for hospital infections, and Structure Therapeutics started a Phase IIa trial of its GLP-1 agonist in obesity and diabetes, with plans for a Phase IIb trial in 2024.

Clinical Trials Diversity & Inclusion

Otsuka/Lundbeck’s Rexulti Has Time To Build A Lead In The Alzheimer’s Agitation Market

The US FDA approved Rexulti as the first drug for agitation in Alzheimer’s disease, a multibillion-dollar market where Lundbeck estimates it could bring in $1bn in annual sales.

Approvals Business Strategies

Supplemental Filings: Pink Sheet’s Notebook on Elon vs. FDA, Audio vs. Video, and More

Califf tweaks his misinformation stump speech, FDA adds to the Twitter COVID vaccine confusion with a tweet to Elon Musk, generic firms are schooled on the difference between a teleconference and a video conference, and other observations from Pink Sheet reporters’ notebooks.

Advisory Committees Vaccines

AbbVie Broadens Qulipta Migraine Indication As Anti-CGRP Competition Grows

AbbVie’s migraine franchise expanded with US FDA approval of Qulipta for chronic migraine prevention, but its CGRP inhibitors are facing off against a pair of rivals acquired by Pfizer last year.

Approvals Launches
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Other Names / Subsidiaries
    • Abide Therapeutics Inc.
    • Alder Biopharmaceuticals, Inc.
    • Chelsea Therapeutics International, Ltd.
    • Lundbeck La Jolla Research Center
    • Lundbeck Seattle Biopharmaceuticals
    • Ovation Pharmaceuticals, Inc
    • Saegis Pharmaceuticals, Inc.
UsernamePublicRestriction

Register